PE20211449A1 - INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSES - Google Patents
INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSESInfo
- Publication number
- PE20211449A1 PE20211449A1 PE2020001395A PE2020001395A PE20211449A1 PE 20211449 A1 PE20211449 A1 PE 20211449A1 PE 2020001395 A PE2020001395 A PE 2020001395A PE 2020001395 A PE2020001395 A PE 2020001395A PE 20211449 A1 PE20211449 A1 PE 20211449A1
- Authority
- PE
- Peru
- Prior art keywords
- cell
- antigen
- adjuvant
- entry
- modified
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Referido a una celula T modificada que comprende un antigeno y un adyuvante, en donde el antigeno es exogeno a la celula T modificada y comprende un epitopo inmunogenico, y en donde el adyuvante esta presente en forma intracelular. Ademas, el antigeno que comprende la secuencia de aminoacidos de cualquiera de las SEQ ID NOs: 18-25. Un proceso que comprende: a) pasar una suspension celular que comprende una celula T de entrada a traves de una constriccion de deformacion celular, en donde un diametro de la constriccion es una funcion de un diametro de la celula T de entrada en la suspension, causando asi perturbaciones de la celula T de entrada suficientemente grandes para que el antigeno y el adyuvante pasen a traves para formar una celula T de entrada perturbada; y b) incubar la celula T de entrada perturbada con el antigeno y el adyuvante durante un tiempo suficiente para permitir que el antigeno y el adyuvante ingresen en la celula T de entrada perturbada; generando asi la celula T modificada. Tambien se refiere a metodos de uso de dichas celulas T para modular una respuesta inmune.Refers to a modified T cell comprising an antigen and an adjuvant, wherein the antigen is exogenous to the modified T cell and comprises an immunogenic epitope, and wherein the adjuvant is present in intracellular form. In addition, the antigen comprising the amino acid sequence of any of SEQ ID NOs: 18-25. A process comprising: a) passing a cell suspension comprising an entry T cell through a cell strain constriction, wherein a diameter of the constriction is a function of a diameter of the entry T cell in the suspension, thereby causing input T cell disturbances large enough for antigen and adjuvant to pass through to form a disturbed input T cell; and b) incubating the disturbed entry T cell with the antigen and adjuvant for a time sufficient to allow the antigen and adjuvant to enter the disturbed entry T cell; thus generating the modified T cell. It also relates to methods of using said T cells to modulate an immune response.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641987P | 2018-03-12 | 2018-03-12 | |
| US201862738941P | 2018-09-28 | 2018-09-28 | |
| US201962738941P | 2019-01-18 | 2019-01-18 | |
| PCT/US2019/021705 WO2019178006A2 (en) | 2018-03-12 | 2019-03-11 | Intracellular delivery of biomolecules to modify immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211449A1 true PE20211449A1 (en) | 2021-08-05 |
Family
ID=77914169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001395A PE20211449A1 (en) | 2018-03-12 | 2019-03-11 | INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSES |
Country Status (1)
| Country | Link |
|---|---|
| PE (1) | PE20211449A1 (en) |
-
2019
- 2019-03-11 PE PE2020001395A patent/PE20211449A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123254T1 (en) | METHODS FOR CELL TRANSFORMATION AND PROCESSING | |
| CO2018006699A2 (en) | Scalable methods to produce a recombinant adeno-associated viral vector (aav) in a serum-free suspension cell culture system suitable for clinical use | |
| CO2020012584A2 (en) | Intracellular supply of biomolecules to modify immune responses | |
| EA201992469A1 (en) | ANTIGEN SPECIFIC IMMUNE EFFECTIVE CELLS | |
| MX2019010575A (en) | Method for producing multispecific antibodies. | |
| AR103162A1 (en) | ANTI-C5 ANTIBODIES AND METHODS FOR USE | |
| PE20191324A1 (en) | OPTIMIZATION OF ANTIBODIES THAT BIND TO THE LYMPHOCYTE ACTIVATION GENE 3 (LAG-3) AND USES OF THEM | |
| EP4289944A3 (en) | Method for preparing genetically-modified t cells which express chimeric antigen receptor | |
| BR112016028512A8 (en) | method of culturing a mammalian cell and method of producing a recombinant protein | |
| WO2014146074A3 (en) | Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens | |
| AR094779A1 (en) | CETUXIMAB WITH MODIFIED GLYCOSILATION AND ITS USES | |
| PE20190415A1 (en) | HUMANIZED ANTI-BASIGIN ANTIBODIES AND THE USE OF THEM | |
| CO2022007238A2 (en) | Chimeric antigen receptor t-cell therapy | |
| MX2021001890A (en) | Production methods for viral vectors. | |
| PE20211449A1 (en) | INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSES | |
| ES2096650T3 (en) | IMPROVEMENT OF THE ASSOCIATION OF EXOGENOUS PEPTIDES WITH MHC CLASS I MOLECULES IN CELLS OF THE IMMUNE SYSTEM. | |
| ES2652267T3 (en) | Method for efficient isolation of microbial DNA from blood | |
| MX2022008298A (en) | Antibody for skewing sex ratio and methods of use thereof. | |
| AR088428A1 (en) | MULTIPLEXED TEST BASED ON SELF-ASSEMBLED SPHERES FOR ANTIGEN SPECIFIC ANTIBODIES | |
| AR110908A1 (en) | PROMOTER CONSTRUCTION FOR SYNTHESIS OF PROTEINS FREE OF CELLS | |
| PL439808A1 (en) | Methods and compositions of cell cultures for the production of antibodies | |
| AR115304A1 (en) | STEM / PROGENITOR CELLS OF THE DUODENAL BRUNNER GLANDS AND METHODS FOR THEIR ISOLATION AND USE | |
| EP3740226A4 (en) | Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same | |
| BR112021021349A2 (en) | Methods of manufacturing cartalogenic cells | |
| JP2015536145A5 (en) |